BCRX

Biocryst Pharmaceuticals Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↓ 1/10
  • Value↓ 1/10
Biocryst Pharmaceuticals sales and earnings growth
BCRX Growth
Low
  • Revenue Y/Y↑ 46.57%
  • EPS Y/Y↓ -565.38%
  • FCF Y/Y↑ 1254.42%
Biocryst Pharmaceuticals gross and profit margin trends
BCRX Profitability
Good
  • Gross margin ↑ 97.80%
  • EPS margin↓ -51.70%
  • ROIC 5Y↓ -3.08%
Biocryst Pharmaceuticals net debt vs free cash flow
BCRX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 2.2
  • Interest coverage↓ -5.0

Biocryst Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks